Vai alla homepage

I migliori medici di Immunoterapia per il cancro alla prostata - TOP-31medici

Il contenuto è conforme alla Politica editoriale di Bookimed ed è revisionato da medici

Fahad Mawlood

Eda Tanrikulu

  • 4.6 Eccellente 514 recensioni
  • 21 anni di esperienza
  • Turchia, Istanbul, Anadolu Medical Center
  • La Dott.ssa Eda Tanrikulu è specializzata in oncologia medica e chemioterapia con un forte focus sull'immunoterapia per il cancro alla prostata presso l'Anadolu Medical Center.

    • Classificata al 3° posto in Turchia nel concorso di specialità minori in oncologia medica
    • Assistente e capo ricercatrice in numerosi studi clinici internazionali
    • In precedenza ha diretto l'unità di oncologia medica presso l'Ospedale di Formazione e Ricerca di Haydarpaşa Numune
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Mustafa Solak

  • 4.6 Eccellente 211 recensioni
  • 20 anni di esperienza
  • Turchia, Istanbul, Hisar Hospital Intercontinental
  • Specializzato in immunoterapia per il cancro alla prostata con formazione presso il Cancer Institute dell'Università di Hacettepe e il MD Anderson Cancer Center.

    • Esperto nel trattamento di vari tipi di cancro, tra cui prostata, seno e polmoni
    • Ha completato una borsa di studio presso il prestigioso Cancer Institute dell'Università di Hacettepe
    • Formazione presso il MD Anderson Cancer Center dell'Università del Texas
    • Lavora presso Hisar Hospital Intercontinental
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ofer Merimsky

  • 4.5 Buono 155 recensioni
  • 41 anni di esperienza
  • accreditamenti:
  • Israele, Tel Aviv, Sourasky Medical Center (Ichilov)
  • Il Prof. Merimsky dirige l'Unità di Oncologia dei Tessuti Molli e delle Ossa presso il Sourasky Medical Center, leader nell'immunoterapia per il cancro alla prostata.

    • Oltre 25 anni di specializzazione in oncologia con un focus sull'immunoterapia
    • Formazione avanzata in oncologia dei sarcomi presso l'Institut Gustave Roussy di Parigi
    • Membro attivo del gruppo di lavoro sui sarcomi dell'ESMO
    • Ha pubblicato ampiamente sull'immunologia dei tumori e il trattamento del cancro
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

David Sarid

  • 4.5 Buono 155 recensioni
  • 38 anni di esperienza
  • accreditamenti:
  • Israele, Tel Aviv, Sourasky Medical Center (Ichilov)
  • Il dott. Sarid è specializzato in immunoterapia del cancro alla prostata presso il Centro Medico Sourasky, con un'ampia formazione in urologia oncologica dall'Università di Oxford.

    • Oncologo senior presso Ichilov dal 2009
    • Ricercatore principale di studi clinici su terapie oncologiche
    • Ha pubblicato oltre 30 articoli sul trattamento del cancro
    • Membro di ESMO e ASCO
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Eslie Perez

  • Nuova
  • 12 anni di esperienza
  • Messico, Porto Vallarta, Holistic Bio Spa®
  • Head of Teaching at the Puerto Vallarta Regional Hospital

    2020-2023

    Medical records manager at the Regional Hospital of Puerto Vallarta 2 months 2020

    General practitioner in private medical office

    2015-2022

    Doctor in charge of weight control clinic

    2013-2014

    Medical assistant in dermatology clinic

    2008-2013

     

    Medical Assistant in Dermatological procedures.

     Medical Assistant in minimally invasive surgical procedures

     Operation of fractional laser machine - IPIXEL-ER and

    facial rejuvenation with IPL.

     Experience in laser hair removal with Intense Pulsed Light and

    radiofrequency

     Experience with ultrasonic cavitation

     Experience with ultraviolet (UV) light phototherapy machine for the

    treatment of psoriasis and vitiligo.

     Experience assisting in Botox and Fillers procedures.

     Biomagnet certified by the Higher Institute of Biomagnetism

    doctor ISAAC GOIZ DURAN

     Experience in clinical records

     Training in continuing education and professional development of teachers

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Prof. Sezer Sağlam

  • 5 Eccellente 2 recensioni
  • 27 anni di esperienza
  • Turchia, Istanbul, Gayrettepe Florence Nightingale Hospital
  • Personal Information 

    Sex:  Male

    Born : 1968 

     

    Professional Experience

    Gayrettepe Florence Nigthingale Hospital

    Medical Oncology Department

    Besiktas/Istanbul/Turkey (ongoing)

     

    Education:

    He became Professor (22/April /2016)

    Medical Oncology

     

    Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

    Istanbul University Oncology Institue,

    Department of Medical Oncology

     

    Medical Oncology Fellowship (December 2001-December2004)

    Istanbul University, Istanbul Medical Faculty

     

    Hemodialysis Traning (May1996-January1997)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Internal Medicine Residency (November 1991-November 1996)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Ege University Medical Faculty (1985-1991)

     

    Professional Experience

    February 1999-November 2001

    Metropolitan Florence Nigthingale Hospital

    American Cancer Center, Gayrettepe/İstanbul

     

    April1997- October 1998

    Bayraktar Dialysis Center

    Güngören/ Istanbul

     

    Membership

    Turkish Medical Oncology Association

    ENET(European Neuroendocrine Tumour Society)

    ESMO

    ASCO

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Abdullah Sakin

  • 4.5 Buono 2 recensioni
  • 19 anni di esperienza
  • Turchia, Istanbul, Medipol Bahçelievler Hospital
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Constantinos Zamboglou

  • Nuova
  • 13 anni di esperienza
  • Cipro, Repubblica di Cipro, German Medical Institute (GMI)
  • Education

    09 / 2004 – 07 / 2006                Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B

    09 / 2006 – 08 / 2008                Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A

    10 / 2008 – 05 / 2013                Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A

    02/ 2009 – 02/2012                   Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, GermanyDoctoral thesis, grade: summa cum laude

    05 / 2018                                      Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg

    01 / 2019                                      Board certification: Radiotherapy and Radiation Oncology

    03 / 2020                                      Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)

    09 / 21 – 08 / 23                         MHBA, Friedrich Alexander University, Nuernberg, Germany

    07 / 2022                                      Completion of ISO 9001:2015 training, Nicosia, Cyprus

    Professional Career

    09 / 2013 – 01 / 2019               Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency                                                

    07 / 2017 – 07 / 2020               Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist

    Since 06 / 2019                          Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant

    01 / 2021 – 12 / 2022                Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist

    01 / 2021 – 12 / 2021                 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany

    Since 01 / 2022                         Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader

    Since 01 / 2022                          German Medical Institute, Limassol, Cyprus, Vice Medical Director

    Professional Memberships and Distinctions

    2010           Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany      

    2017           Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany

    2019           Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany

    2020           Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)

    2020           Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)

    2021           Invited member of the ESTRO-ACROP guideline committee for prostate cancer

    2021           Best Abstract, EMUC congress 2021, Athens, Greece

    2023           Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation

    2023           Invited member of the ESTRO focus group “Urology”

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Sinan Karaaslan

  • 4.6 Eccellente 514 recensioni
  • 29 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Anadolu Medical Center
  • Il dottor Sinan Karaaslan è un oncologo esperto specializzato nei tumori del sistema urogenitale, incluso il cancro alla prostata, presso l'Anadolu Medical Center.

    • Oltre 13 anni di esperienza in oncologia medica
    • Formazione specialistica presso la Facoltà di Medicina Cerrahpaşa dell'Università di Istanbul
    • Membro della Società Turca di Oncologia Medica
    • Si concentra su immunoterapia e terapie mirate
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Yesim Yildirim

  • Medico leader per Immunoterapia per il cancro alla prostata
  • 4.6 Eccellente 514 recensioni
  • 22 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Anadolu Medical Center
  • La Professoressa Yesim Yildirim è specializzata in immunoterapia per il cancro alla prostata presso l'Anadolu Medical Center, con oltre 13 anni di pratica oncologica focalizzata.

    • Membro della Società Europea di Oncologia Medica (ESMO)
    • Autrice di oltre 80 pubblicazioni internazionali, inclusa la co-autoria di manuali di cura del cancro
    • Formata presso il Mount Vernon Cancer Center per l'immunoterapia del melanoma e del cancro renale
    • Professoressa presso l'Università di Haliç, combina la ricerca accademica con la pratica clinica
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Mustafa Serkan Alemdar

  • 4.5 Buono 6 recensioni
  • 20 anni di esperienza
  • Turchia, The text "Antalya" is a city name and not a medical term. Therefore, it does not require translation into Italian as a medical term. If you need assistance with another type of translation, please provide additional details., Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Wolfgang Köstler

  • 4.7 Eccellente 154 recensioni
  • 22 anni di esperienza
  • Austria, Vienna in Italian is "Vienna". However, since we're discussing the term in a medical context, it's important to note that "Vienna" refers to the city and does not have a specific medical translation. The context indicates geographic location rather than a medical condition. If you meant "vein" in a medical context, the Italian translation would be "vena"., Wiener Privatklinik
  • Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Phd Viola Fox

  • 4.7 Eccellente 61 recensioni
  • 14 anni di esperienza
  • Jerman, Solingen, Medical Center in Solingen
  • La dottoressa Viola Fox è specializzata in immunoterapia per il cancro alla prostata, combinando la diagnostica molecolare con piani di trattamento personalizzati presso il Medical Center di Solingen.

    • Oltre 16 anni di esperienza in oncologia e immunoterapia
    • Medico capo presso un centro oncologico interdisciplinare certificato
    • Esperta in ricerca di biologia molecolare per trattamenti oncologici
    • Membro dell'American Association for Cancer Research
    • Specialista qualificata in genetica
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Tahsin Ozatli

  • 4.4 Buono 17 recensioni
  • 2016 anni di esperienza
  • Turchia, Istanbul, Istinye University Liv Hospital Bahcesehir
  • Oncologist
Visita dal medico
Prezzo su richiesta
Informazioni

Cemil Bilir

  • 5 Eccellente 1 recensioni
  • 21 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Ercan Ozden

  • 5 Eccellente 1 recensioni
  • 27 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Atakan Topcu

  • 5 Eccellente 3 recensioni
  • 13 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Nail Paksoy

  • 4.5 Buono 2 recensioni
  • 15 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Irfan Cicin

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Muhammed Mustafa Atci

  • 5 Eccellente 1 recensioni
  • 15 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Come scegliere il medico e la clinica giusti: consigli degli esperti

Quando scegli un medico o una clinica, tieni presente questi punti chiave:
Controlla le credenziali
Verifica le certificazioni di enti come ISAPS, JCI o degli ordini medici pertinenti.
Verifica i tassi di successo
Scegli medici con grande esperienza e comprovata competenza nel trattamento specifico.
Leggi le recensioni dei pazienti
Recensioni reali dei pazienti Bookimed per conoscere la loro esperienza.
Assicura una comunicazione efficace
Scegli cliniche che offrono servizio di traduzione per facilitare il trattamento.
Chiedi informazioni sui servizi
Conferma se il prezzo include servizi come alloggio, trasferimenti locali e assistenza post-trattamento per evitare costi nascosti.
Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.
Yan Matsiivskiy
Capo del team dei coordinatori medici

Bookimed Insights: Principali specialisti in Immunoterapia per il cancro alla prostata nel mondo (2026)

Bookimed ha coordinato 45 richieste per Immunoterapia per il cancro alla prostata a livello mondiale, collaborando con 31 esperti di primo piano. I medici in questa tabella sono selezionati per le loro credenziali internazionali, esperienza clinica e risultati ottenuti. Il ranking globale di 2026 è elaborato con dati verificati su casi reali e programmi aggiornati delle nostre cliniche partner.
MedicoesperienzaBuona scelta perCosa li distingueClinica e posizioneConsulto
21 anni di esperienzaImmunoterapia per il cancro alla prostataClassificatosi al 3º posto nell'esame di oncologia medica in Turchia con esperienza di ricerca internazionale. Ha diretto l'unità di oncologia di un grande ospedale.
Turchia
da $160
20 anni di esperienzaImmunoterapia per il cancro alla prostataSpecializzato in immunoterapia del cancro alla prostata con formazione presso il MD Anderson Cancer Center. Esperto in diversi tipi di cancro con borsa di studio presso l'Università di Hacettepe.
Turchia
da $100
41 anni di esperienzaCasi resistenti all'immunoterapiaSpecializzato in casi di cancro alla prostata resistenti all'immunoterapia. Responsabile dell'Unità di Oncologia dei Tessuti Molli e delle Ossa presso il Sourasky Medical Center. Membro della facoltà del gruppo Sarcoma dell'ESMO.
Israele
da $950
38 anni di esperienzaImmunoterapia del cancro alla prostataOxford-formato in urologia oncologica, conduce sperimentazioni cliniche in immunoterapia. Ricercatore principale con oltre 30 pubblicazioni. Membro dell'ESMO e ASCO.
Israele
Prezzo su richiesta
29 anni di esperienzaImmunoterapia per il cancro alla prostataSpecializzato in tumori urogenitali con oltre 13 anni di esperienza mirata in oncologia. Formato presso la Cerrahpaşa Medical School, un importante centro oncologico turco.
Turchia
da $140
22 anni di esperienza<p>Immunoterapia per il cancro alla prostata</p>Testo_dottore: Specialista certificato ESMO con formazione avanzata in immunoterapia del cancro. Ampiamente pubblicato e coautore di 'Manuale di Trattamento Avanzato per la Cura del Cancro'.
Turchia
da $250
14 anni di esperienzaPiani personalizzati di immunoterapiaCombina l'immunoterapia con la diagnostica molecolare per un trattamento personalizzato del cancro alla prostata. Primario in un centro oncologico certificato e ricercatore attivo.
Jerman
Prezzo su richiesta